Premium
Graphene‐Oxide‐Modified Lanthanide Nanoprobes for Tumor‐Targeted Visible/NIR‐II Luminescence Imaging
Author(s) -
Song Xiaorong,
Li Shihua,
Guo Hanhan,
You Wenwu,
Shang Xiaoying,
Li Renfu,
Tu Datao,
Zheng Wei,
Chen Zhuo,
Yang Huanghao,
Chen Xueyuan
Publication year - 2019
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201909416
Subject(s) - biocompatibility , lanthanide , nanotechnology , luminescence , materials science , graphene , nanoparticle , oxide , dispersity , nanocrystal , photon upconversion , chemistry , optoelectronics , organic chemistry , polymer chemistry , ion , metallurgy
The synthesis of hydrophilic lanthanide‐doped nanocrystals (Ln 3+ ‐NCs) with molecular recognition ability for bioimaging currently remains a challenge. Herein, we present an effective strategy to circumvent this bottleneck by encapsulating Ln 3+ ‐NCs in graphene oxide (NCs@GO). Monodisperse NCs@GO was prepared by optimizing GO size and core–shell structure of NaYF 4 :Yb,Er@NaYF 4 , thus combining the intense visible/near‐infrared II (NIR‐II) luminescence of NCs and the unique surface properties and biomedical functions of GO. Such nanostructures not only feature broad solvent dispersibility, efficient cell uptake, and excellent biocompatibility but also enable further modifications with various agents such as DNA, proteins, or nanoparticles without tedious procedures. Moreover, we demonstrate in proof‐of‐concept experiments that NCs@GO can realize simultaneous intracellular tracking and microRNA‐21 visualization, as well as highly sensitive in vivo tumor‐targeted NIR‐II imaging at 1525 nm.